Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Association between TLR9 rs5743836 polymorphism and risk of recurrent venous thromboembolism

Ahmad, Abrar LU ; Sundquist, Kristina LU ; Zöller, Bengt LU orcid ; Svensson, Peter J LU ; Sundquist, Jan LU and Memon, Ashfaque A LU orcid (2017) In Journal of Thrombosis and Thrombolysis 44(1). p.130-138
Abstract

Recent gene knockout studies on mice have shown the role of toll-like receptor 9 (TLR9) in resolution of venous thromboembolism (VTE) through sterile inflammation. However, the role of a putative functional TLR9 polymorphism (rs5743836) in risk assessment of VTE recurrence remains unknown. The aim of our study was to investigate the TLR9 rs5743836 polymorphism in VTE patients and its association with the risk of VTE recurrence. We analyzed TLR9 rs5743836 polymorphism in Malmö thrombophilia study patients; a prospective follow-up study of 1465 VTE patients by Taqman PCR. From a total of 1465 VTE patients, those who had VTE before inclusion and those who died or had VTE recurrence during anticoagulant treatment were excluded (n = 415).... (More)

Recent gene knockout studies on mice have shown the role of toll-like receptor 9 (TLR9) in resolution of venous thromboembolism (VTE) through sterile inflammation. However, the role of a putative functional TLR9 polymorphism (rs5743836) in risk assessment of VTE recurrence remains unknown. The aim of our study was to investigate the TLR9 rs5743836 polymorphism in VTE patients and its association with the risk of VTE recurrence. We analyzed TLR9 rs5743836 polymorphism in Malmö thrombophilia study patients; a prospective follow-up study of 1465 VTE patients by Taqman PCR. From a total of 1465 VTE patients, those who had VTE before inclusion and those who died or had VTE recurrence during anticoagulant treatment were excluded (n = 415). Cox regression analyses were performed on the remaining 1050 VTE patients, including 126 (12.5%) patients that had recurrent VTE during follow-up period. TLR9 polymorphism was significantly associated with higher risk of VTE recurrence in female patients (HR 3.46, 95% CI 1.06-11.33) independent of acquired risk factors for VTE, family history, risk of thrombophilia and deep vein thrombosis (DVT) location. Similarly, in unprovoked VTE patients, TLR9 polymorphism was significantly associated with higher risk of VTE recurrence in female patients (HR 5.94, 95% CI 1.25-28.13) after adjusting for family history, risk of thrombophilia and DVT location. No association between TLR9 polymorphism and risk of VTE recurrence was found in male patients. Our results suggest that TLR9 rs5743836 polymorphism is an independent risk factor for VTE recurrence in female patients but not in males.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Journal Article
in
Journal of Thrombosis and Thrombolysis
volume
44
issue
1
pages
130 - 138
publisher
Springer
external identifiers
  • scopus:85015615910
  • wos:000403207000018
  • pmid:28321710
ISSN
1573-742X
DOI
10.1007/s11239-017-1491-3
project
Identification of diagnostic and prognostic biomarkers of venous thromboembolism and its recurrence
Genetic risk factor of venous thromboembolism and its recurrence
language
English
LU publication?
yes
id
3bf5459c-dc25-42f1-87cb-7a81c156ed8a
date added to LUP
2017-05-24 15:56:14
date last changed
2024-02-29 15:38:05
@article{3bf5459c-dc25-42f1-87cb-7a81c156ed8a,
  abstract     = {{<p>Recent gene knockout studies on mice have shown the role of toll-like receptor 9 (TLR9) in resolution of venous thromboembolism (VTE) through sterile inflammation. However, the role of a putative functional TLR9 polymorphism (rs5743836) in risk assessment of VTE recurrence remains unknown. The aim of our study was to investigate the TLR9 rs5743836 polymorphism in VTE patients and its association with the risk of VTE recurrence. We analyzed TLR9 rs5743836 polymorphism in Malmö thrombophilia study patients; a prospective follow-up study of 1465 VTE patients by Taqman PCR. From a total of 1465 VTE patients, those who had VTE before inclusion and those who died or had VTE recurrence during anticoagulant treatment were excluded (n = 415). Cox regression analyses were performed on the remaining 1050 VTE patients, including 126 (12.5%) patients that had recurrent VTE during follow-up period. TLR9 polymorphism was significantly associated with higher risk of VTE recurrence in female patients (HR 3.46, 95% CI 1.06-11.33) independent of acquired risk factors for VTE, family history, risk of thrombophilia and deep vein thrombosis (DVT) location. Similarly, in unprovoked VTE patients, TLR9 polymorphism was significantly associated with higher risk of VTE recurrence in female patients (HR 5.94, 95% CI 1.25-28.13) after adjusting for family history, risk of thrombophilia and DVT location. No association between TLR9 polymorphism and risk of VTE recurrence was found in male patients. Our results suggest that TLR9 rs5743836 polymorphism is an independent risk factor for VTE recurrence in female patients but not in males.</p>}},
  author       = {{Ahmad, Abrar and Sundquist, Kristina and Zöller, Bengt and Svensson, Peter J and Sundquist, Jan and Memon, Ashfaque A}},
  issn         = {{1573-742X}},
  keywords     = {{Journal Article}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{130--138}},
  publisher    = {{Springer}},
  series       = {{Journal of Thrombosis and Thrombolysis}},
  title        = {{Association between TLR9 rs5743836 polymorphism and risk of recurrent venous thromboembolism}},
  url          = {{http://dx.doi.org/10.1007/s11239-017-1491-3}},
  doi          = {{10.1007/s11239-017-1491-3}},
  volume       = {{44}},
  year         = {{2017}},
}